+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biosimilar Monoclonal Antibodies Market by Drug Class, Application - Global Forecast 2025-2030- Product Image
Biosimilar Monoclonal Antibodies Market by Drug Class, Application - Global Forecast 2025-2030- Product Image
Sale

Biosimilar Monoclonal Antibodies Market by Drug Class, Application - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 198 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6010903
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biosimilar Monoclonal Antibodies Market grew from USD 7.69 billion in 2023 to USD 9.47 billion in 2024. It is expected to continue growing at a CAGR of 23.19%, reaching USD 33.14 billion by 2030.

Biosimilar monoclonal antibodies (mAbs) represent a rapidly growing segment within the biopharmaceutical sector, focusing on drugs designed to be almost identical to existing, approved monoclonal antibody therapies. Their emergence is driven by the necessity to provide cost-effective alternatives to original biologics whose patents have expired, thus enhancing patient access to essential treatments for chronic diseases like cancer and autoimmune disorders. The application scope spans oncology, immunology, infectious diseases, and beyond, offering remarkable potential to alleviate healthcare burdens. End-use primarily involves pharmaceutical companies, healthcare providers, and research institutions aiming to integrate these cost-efficient options into their treatment regimens. Key growth influencers in this market include an increasing number of biologics going off-patent, continual advancements in biotechnology, and supportive regulatory frameworks across different geographies. Additionally, the rising prevalence of chronic diseases propels demand. Potential opportunities lie in emerging markets where healthcare infrastructure is improving, and regulations are aligning with biosimilar adoption. Companies can strategically expand by forming partnerships and investing in market education initiatives to overcome regulatory and skepticism challenges. However, market growth is hampered by regulatory complexities, high development costs, and stringent requirements for demonstrating biosimilarity and interchangeability. Intellectual property lawsuits present another significant hurdle. Areas ripe for innovation and research include enhancing production technologies to lower costs further, developing biosimilars for mAbs that treat rare conditions, and exploring novel delivery mechanisms to improve patient compliance. The market landscape is competitive, with numerous established pharmaceutical giants and agile biotech firms. To successfully navigate this dynamic environment, companies should focus on strategic collaborations to leverage technology advancements, strengthen distribution networks, and prioritize robust clinical development pipelines. Ultimately, being proactive in addressing regulatory challenges and fostering industry-wide acceptance through transparent communication will be crucial in unlocking the full potential of biosimilar monoclonal antibodies.

Understanding Market Dynamics in the Biosimilar Monoclonal Antibodies Market

The Biosimilar Monoclonal Antibodies Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing prevalence of cost-efficient biosimilar monoclonal antibodies
    • Growth in geriatric population and rising incidence of cancer and other chronic diseases
    • Increasing healthcare expenditure in economies
  • Market Restraints
    • Government regulations towards the absence of pre-analytical tests
  • Market Opportunities
    • Rising number of inorganic strategies for the expansion of production facility
    • Focus on R&D to introduce innovative product pipeline
  • Market Challenges
    • Complexities associated with manufacturing processes

Exploring Porter’s Five Forces for the Biosimilar Monoclonal Antibodies Market

Porter’s Five Forces framework further strengthens the insights of the Biosimilar Monoclonal Antibodies Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Biosimilar Monoclonal Antibodies Market

External macro-environmental factors deeply influence the performance of the Biosimilar Monoclonal Antibodies Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Biosimilar Monoclonal Antibodies Market

The Biosimilar Monoclonal Antibodies Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Biosimilar Monoclonal Antibodies Market

The Biosimilar Monoclonal Antibodies Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Biosimilar Monoclonal Antibodies Market

The Biosimilar Monoclonal Antibodies Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biosimilar Monoclonal Antibodies Market, highlighting leading vendors and their innovative profiles. These include 3SBio Inc., AbbVie, Inc., Amgen Inc., Biocon Limited, BioXpress Therapeutics SA, C.H. Boehringer Sohn AG & Co. KG, Celltrion Healthcare Co Ltd., Coherus BioSciences, Inc., Dr. Reddy’s Laboratories Ltd, Genor BioPharma Co. Ltd, Hisun Pharmaceutical, Intas Pharmaceuticals Limited, Novartis AG, Pfizer, Inc., Reliance Life Sciences, and Samsung Biologics.

Market Segmentation & Coverage

This research report categorizes the Biosimilar Monoclonal Antibodies Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Drug Class
    • Abciximab
    • Adalimumab
    • Bevacizumab
    • Infliximab
    • Rituximab
    • Trastuzumab
  • Application
    • Diagnostic
      • MABs in Biochemical Analysis
        • Cancers
        • Hormonal Disorders
        • Infectious Diseases
        • Pregnancy
      • MABs in Diagnostic Imaging
        • Atherosclerosis
        • Bacterial Infections
        • Cancers
        • Cardiovascular Diseases
        • Deep Vein Thrombosis
    • Protein Purification
    • Therapeutic
      • MABs as Direct Therapeutic Agents
      • MABs as Targeting Agents in Therapy
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cost-efficient biosimilar monoclonal antibodies
5.1.1.2. Growth in geriatric population and rising incidence of cancer and other chronic diseases
5.1.1.3. Increasing healthcare expenditure in economies
5.1.2. Restraints
5.1.2.1. Government regulations towards the absence of pre-analytical tests
5.1.3. Opportunities
5.1.3.1. Rising number of inorganic strategies for the expansion of production facility
5.1.3.2. Focus on R&D to introduce innovative product pipeline
5.1.4. Challenges
5.1.4.1. Complexities associated with manufacturing processes
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Biosimilar Monoclonal Antibodies Market, by Drug Class
6.1. Introduction
6.2. Abciximab
6.3. Adalimumab
6.4. Bevacizumab
6.5. Infliximab
6.6. Rituximab
6.7. Trastuzumab
7. Biosimilar Monoclonal Antibodies Market, by Application
7.1. Introduction
7.2. Diagnostic
7.2.1. MABs in Biochemical Analysis
7.2.1.1. Cancers
7.2.1.2. Hormonal Disorders
7.2.1.3. Infectious Diseases
7.2.1.4. Pregnancy
7.2.2. MABs in Diagnostic Imaging
7.2.2.1. Atherosclerosis
7.2.2.2. Bacterial Infections
7.2.2.3. Cancers
7.2.2.4. Cardiovascular Diseases
7.2.2.5. Deep Vein Thrombosis
7.3. Protein Purification
7.4. Therapeutic
7.4.1. MABs as Direct Therapeutic Agents
7.4.2. MABs as Targeting Agents in Therapy
8. Americas Biosimilar Monoclonal Antibodies Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Biosimilar Monoclonal Antibodies Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Biosimilar Monoclonal Antibodies Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.4. Strategy Analysis & Recommendation
LIST OF FIGURES
FIGURE 1. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET RESEARCH PROCESS
FIGURE 2. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 11. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 13. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 19. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
TABLE 1. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET DYNAMICS
TABLE 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ABCIXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TRASTUZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PREGNANCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CANCERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY PROTEIN PURIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS DIRECT THERAPEUTIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS AS TARGETING AGENTS IN THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 54. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 55. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 57. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 58. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 59. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 60. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 61. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 63. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 64. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 65. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 74. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 78. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 79. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 80. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 81. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 82. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 83. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 84. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 85. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 86. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 87. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 88. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 89. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 90. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 91. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 92. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 93. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 94. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 95. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 96. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 97. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 98. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 99. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 100. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 101. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 102. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 103. INDONESIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 104. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 105. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 106. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 107. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 108. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 109. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 110. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 111. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 112. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 113. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 114. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 115. MALAYSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 116. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 117. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 118. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 119. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 120. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 121. PHILIPPINES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 122. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 123. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 124. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 125. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 126. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 127. SINGAPORE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 128. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 129. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 130. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 131. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 132. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 133. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 134. TAIWAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 135. TAIWAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 136. TAIWAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 137. TAIWAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 138. TAIWAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 139. TAIWAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 140. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 141. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 142. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 143. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 144. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 145. THAILAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 146. VIETNAM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 147. VIETNAM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. VIETNAM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 149. VIETNAM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 150. VIETNAM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 151. VIETNAM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 159. DENMARK BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 160. DENMARK BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 161. DENMARK BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 162. DENMARK BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 163. DENMARK BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 164. DENMARK BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 165. EGYPT BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 166. EGYPT BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 167. EGYPT BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 168. EGYPT BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 169. EGYPT BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 170. EGYPT BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 171. FINLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 172. FINLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 173. FINLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 174. FINLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 175. FINLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 176. FINLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 177. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 178. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 179. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 180. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 181. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 182. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 183. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 184. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 185. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 186. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 187. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 188. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 189. ISRAEL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 190. ISRAEL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 191. ISRAEL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 192. ISRAEL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 193. ISRAEL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 194. ISRAEL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 195. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 196. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 197. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 198. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 199. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 200. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 213. NORWAY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 214. NORWAY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 215. NORWAY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 216. NORWAY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 217. NORWAY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 218. NORWAY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 219. POLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 220. POLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 221. POLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 222. POLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 223. POLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 224. POLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 225. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 226. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 227. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 228. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 229. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 230. QATAR BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 236. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 242. SAUDI ARABIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 248. SOUTH AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 249. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 250. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 251. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 252. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 253. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 254. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 260. SWEDEN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 266. SWITZERLAND BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 267. TURKEY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 268. TURKEY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 269. TURKEY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 270. TURKEY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 271. TURKEY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 272. TURKEY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 280. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DIAGNOSTIC, 2018-2030 (USD MILLION)
TABLE 282. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN BIOCHEMICAL ANALYSIS, 2018-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MABS IN DIAGNOSTIC IMAGING, 2018-2030 (USD MILLION)
TABLE 284. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 285. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
TABLE 286. BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Biosimilar Monoclonal Antibodies market, which are profiled in this report, include:
  • 3SBio Inc.
  • AbbVie, Inc.
  • Amgen Inc.
  • Biocon Limited
  • BioXpress Therapeutics SA
  • C.H. Boehringer Sohn AG & Co. KG
  • Celltrion Healthcare Co Ltd.
  • Coherus BioSciences, Inc.
  • Dr. Reddy’s Laboratories Ltd
  • Genor BioPharma Co. Ltd
  • Hisun Pharmaceutical
  • Intas Pharmaceuticals Limited
  • Novartis AG
  • Pfizer, Inc.
  • Reliance Life Sciences
  • Samsung Biologics

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages198
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 9.47 Billion
Forecasted Market Value ( USD ) by 2030 $ 33.14 Billion
Compound Annual Growth Rate23.1%
Regions CoveredGlobal
No. of Companies Mentioned16

Related Topics

Related Reports

Monoclonal Antibodies (MAs) Global Market Report 2024 - Product Image

Monoclonal Antibodies (MAs) Global Market Report 2024

  • Report
  • 250 Pages
  • Global
From
Monoclonal Antibodies Market by Source Type, Production Type, Indication, End-User - Global Forecast 2025-2030 - Product Image

Monoclonal Antibodies Market by Source Type, Production Type, Indication, End-User - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Biosimilars Market by Product, Indication, Manufacturing - Global Forecast 2025-2030 - Product Image

Biosimilars Market by Product, Indication, Manufacturing - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
Biosimilars - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Biosimilars - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 100 Pages
  • Global
From
Monoclonal Antibodies Market Report and Forecast 2024-2032 - Product Image

Monoclonal Antibodies Market Report and Forecast 2024-2032

  • Report
  • 160 Pages
  • Global
From

About the Monoclonal Antibodies Market

Biosimilar Monoclonal Antibodies (mAbs) are biotechnological products that are similar to existing monoclonal antibodies (mAbs) that are already approved for use in humans. Biosimilar mAbs are developed using recombinant DNA technology and are designed to have the same structure and function as the original mAbs. Biosimilar mAbs are used to treat a variety of diseases, including cancer, autoimmune diseases, and infectious diseases. They are also used in research and development of new treatments. The biosimilar mAbs market is growing rapidly due to the increasing demand for mAbs in the treatment of various diseases. The market is expected to continue to grow as more mAbs are developed and approved for use in humans. Additionally, the increasing demand for mAbs in research and development is expected to drive the growth of the market. Some companies in the biosimilar mAbs market include Amgen, Biogen, Merck, Pfizer, and Novartis. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.